Genital Warts – Pipeline Insight, 2020
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Genital Warts – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Genital Warts: Overview
Genital warts are the most common viral sexually transmitted infection (STI). They’re caused by the human papilloma virus (HPV) which can be passed on during sexual contact. Not everyone who has the virus develops genital warts. For most people, including those who have visible warts, the virus will be cleared from the body over time. It’s rare for genital warts to cause any long-term health problems.
Symptoms
Symptoms include:
The main check for genital warts is for a doctor or nurse to look at the warts. They may do this using a magnifying lens. The patient may also need an internal examination of the vagina or the anus to see if there are any warts inside. Rarely, it may be necessary to take a biopsy (small sample) of the wart for closer examination. Depending on the area being examined, a local anaesthetic may be used.
Treatment
The sooner genital warts are treated, the easier they are to get rid of. There are two main types of treatment for genital warts. The type of treatment you receive will depend on the type of warts you have and where the warts are. Treatments include:
This segment of the Genital Warts report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Genital Warts Emerging Drugs
Further product details are provided in the report
Genital Warts: Therapeutic Assessment
This segment of the report provides insights about the different Genital Warts drugs segregated based on following parameters that define the scope of the report, such as:
Genital Warts: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II I, preclinical and discovery stage. It also analyses Genital Warts therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Warts drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Genital Warts – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Genital Warts: Overview
Genital warts are the most common viral sexually transmitted infection (STI). They’re caused by the human papilloma virus (HPV) which can be passed on during sexual contact. Not everyone who has the virus develops genital warts. For most people, including those who have visible warts, the virus will be cleared from the body over time. It’s rare for genital warts to cause any long-term health problems.
Symptoms
Symptoms include:
- One or more small, flesh-coloured or grey painless growths or lumps around your vagina, penis, anus or upper thighs
- Itching or bleeding from your genitals or anus
- A change to your normal flow of pee (for example, sideways), that doesn't go away.
The main check for genital warts is for a doctor or nurse to look at the warts. They may do this using a magnifying lens. The patient may also need an internal examination of the vagina or the anus to see if there are any warts inside. Rarely, it may be necessary to take a biopsy (small sample) of the wart for closer examination. Depending on the area being examined, a local anaesthetic may be used.
Treatment
The sooner genital warts are treated, the easier they are to get rid of. There are two main types of treatment for genital warts. The type of treatment you receive will depend on the type of warts you have and where the warts are. Treatments include:
- Applying a cream, lotion or chemicals to the warts
- Destroying the warts by freezing, heating or removing them.
This segment of the Genital Warts report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Genital Warts Emerging Drugs
- VP-102: Verrica Pharmaceuticals
- SB206: Novan
- CB-06-02: Cassiopea
Further product details are provided in the report
Genital Warts: Therapeutic Assessment
This segment of the report provides insights about the different Genital Warts drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Genital Warts
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravenius
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Genital Warts: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II I, preclinical and discovery stage. It also analyses Genital Warts therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Warts drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Genital Warts R&D. The therapies under development are focused on novel approaches to treat/improve Genital Warts.
- In July 2018, Cassiopea announced that the proof of concept phase II clinical trial for its CB-06-02 topical 15% immune modulator tellurium-based gel for the treatment of external genital warts in women demonstrated statistically significant successful complete clearance rates in the PP population and successful complete clearance rates in the ITT population.
- Genital Warts Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Genital Warts drugs?
- How many Genital Warts drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital Warts?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Genital Warts therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Genital Warts and their status?
- What are the key designations that have been granted to the emerging drugs?
- ViroXis Corporation
- bioRASI, LLC
- Verrica Pharmaceuticals Inc.
- Orgenesis
- Heber Biotec
- Cassiopea
- Novan
- Peritech Pharma
- Novartis
- VIR007
- Ranpirnase
- CIGB 300
- AS 101
- VP-102
- SB206
- PP 210
- LFX 453
Introduction
Executive Summary
Genital Warts: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Genital Warts – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Genital Warts companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Genital Warts Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
VP-102: Verrica Pharmaceuticals
Product Description
Research and Development
Product Development Activities
SB206: Novan
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Genital Warts Key Companies
Genital Warts Key Products
Genital Warts- Unmet Needs
Genital Warts- Market Drivers and Barriers
Genital Warts- Future Perspectives and Conclusion
Genital Warts Analyst Views
Genital Warts Key Companies
Appendix
Executive Summary
Genital Warts: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Genital Warts – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Genital Warts companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Genital Warts Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
VP-102: Verrica Pharmaceuticals
Product Description
Research and Development
Product Development Activities
SB206: Novan
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Genital Warts Key Companies
Genital Warts Key Products
Genital Warts- Unmet Needs
Genital Warts- Market Drivers and Barriers
Genital Warts- Future Perspectives and Conclusion
Genital Warts Analyst Views
Genital Warts Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Genital Warts
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Genital Warts
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Genital Warts
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Genital Warts
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products